Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CryoLife has signed an exclusive three-year agreement with Medafor to distribute its microporous polysaccharide hemostatic agent for use in cardiac and vascular surgery in the US and for cardiac, vascular and general surgery, other than orthopaedic and ear, nose and throat surgery, outside the US (excluding Japan and China).
Subscribe to our email newsletter
CryoLife expects to begin distributing Hemostase microporous polysaccharide hemospheres (MPH) in the US in the second quarter of 2008, except to approximately 41 hospitals for which Medafor will retain distribution rights until no later than December 31, 2008.
Outside of the US, CryoLife expects to begin distributing Hemostase MPH in Canada, UK and Germany in the second quarter of 2008, with distribution in other markets beginning in 2009. Department of Defense hospitals are excluded from CryoLife’s territory under the distribution agreement, but Veterans’s Administration Hospitals are included.
Steven Anderson, president and CEO of CryoLife, said: “Hemostase MPH gives surgeons the ability to quickly control active surgical bleeding, making it the perfect complement to CryoLife’s BioGlue product line, which is much stronger and provides both tissue reinforcement and sealant capabilities.”